Opyl Announces AI Powered COVID-19 Clinical Trial Forecaster

asx news Sep 03, 2020

Published by Anthony Di Pizio

ADS Capital offers general market news and also research on specific stocks. Invest with us to get full access!

Did you know we can research stocks for you? Give it a try!

The contents of the below article do not represent an endorsement of the company by ADS Capital or its associates. 

The News

Melbourne, Australia based Opyl (ASX:OPL) today announced that its Artificial Intelligence (AI) software can make ''probability of success'' predictions on the likelihood of a vaccine or therapy succeeding in clinical trials. They have focused this announcement on COVID-19 but says the software may be used for any clinical trial.

The company claims to have run software tests investigating the 475 registered COVID-19 clinical trials currently underway and:

  1. Has identified the two vaccine candidates most likely to succeed
  2. Determined that at least one antibody therapy has the best probability of success in Phase III trials
  3. Therapies show a much...
Continue Reading...

Does PointsBet’s New Deal Warrant A $2 Billion Valuation?

news Sep 03, 2020

Published by Anthony Di Pizio

ADS Capital offers general market news and also research on specific stocks. Join one of our partner brokers to get full access!

SelfWealth

CMC Markets

NBC Sports + PointsBet

US broadcaster NBC has agreed to make PointsBet Holdings (ASX:PBH) the official betting partner of its sports division, NBC Sports, with rights to various platforms across the network. Important deal points:

  • NBC currently has the largest sports audience in the US with 184 million viewers
  • PBH committed to spending US$393 million over 5 years on marketing with NBC, offset by an NBC equity subscription plus options to be (potentially) exercised
  • NBC takes on a 4.9% shareholding in PBH, with 66.88 million additional options maturing in 5 years
  • NBC has some key asset rights expiring in 2022, including NFL and English Premier League (EPL)

At face value, this deal is groundbreaking and it's not surprising PBH shares rose from $7.50 to $14.00 the day of the announcement,...

Continue Reading...

Abbott Labs Receives FDA Approval For COVID-19 Rapid Test

news Aug 30, 2020

Published by Anthony Di Pizio

Abbott's Rapid Test Breakthrough

On August 26th Abbott Laboratories announced that its BinaxNOW COVID-19 test received Emergency Use Authorization (EUA) from the FDA. This is the first approved test that doesn't require laboratory instrumentation to detect active Coronavirus infections in patients, meaning it could be one key to reopening economies and borders.

The test is the size of a credit card and can deliver a result in 15 minutes. It requires a nasal swab which is then tested using Abbott’s proven lateral flow technology to detect antigens. If the patient is negative, they will receive a special QR code direct to an Abbott-designed app on their phone (called NAVICA) which organisations can scan for confirmation. The QR code will come with an expiration date determined by the requirements of the given organisation. 

Right now, the test only detects infections within 7 days of someone showing symptoms and may only be...

Continue Reading...
1 2
Close

Subscribe to ADS Capital news

Keep up to date with ADS Capital news articles.